The combination of TOX3-WDR5/ABCG2 signaling axis could not only be considered as a group of combinational candidate therapeutic targets in anti-CRC therapy, but also serve as a group of more efficient cascade predictors for the survival of CRC patients with recurrence or metastasis. This evidence concerns the gene TOX3 and colorectal carcinoma.